# CJC-1295 with DAC: why the rise lasts

> CJC-1295 and albumin | Ascending Peptides — Ascending Peptides examines CJC-1295 with DAC: albumin binding, a prolonged hormone response, blood-protein changes and the gaps around human benefit.

Albumin helps a short hormonal message persist. I respect the albumin chemistry; the claims gathered around it face a harder test.

## Albumin binding

CJC-1295 copies the active part of growth hormone-releasing hormone, the signal that prompts the pituitary to release growth hormone. The copy has substitutions that slow its breakdown. DAC adds an attachment to albumin, a protein already circulating in blood; without that attachment, Modified GRF (1-29), often called CJC-1295 no-DAC, is short-acting. The [review of growth hormone-releasing hormone and its analogues](https://pubmed.ncbi.nlm.nih.gov/39537825/) places these designs in their broader pharmacological setting.

The distinction matters before any discussion of results. The prolonged response in the early human papers belongs to the albumin-binding form. Moving its duration across to the no-DAC form loses the very feature that made the experiment possible. That casual interchange of names makes me distrustful of an explanation before it reaches the result.

## The prolonged hormonal response

The [2006 healthy-adult study](https://pubmed.ncbi.nlm.nih.gov/16352683/) found elevated growth hormone for six days or more and elevated IGF-1 for nine through eleven days after a single administration. Larger study amounts produced greater rises. Those are hormone measurements made under controlled conditions; they establish duration and response, while leaving sleep, strength and recovery untested.

A [separate study of healthy men aged 20–40](https://pubmed.ncbi.nlm.nih.gov/17018654/) examined the shape of secretion one week later. Mean growth hormone rose by about 46% and IGF-1 by about 45%, alongside an approximately 7.5-fold rise in the basal level. Pulse frequency and magnitude showed no significant change.

Sustained stimulation sounds as though it ought to produce a smooth output. The continuing bursts complicate that picture. They also make the baseline worth inspecting: a substantial change can happen in the intervals without a corresponding change in the pulses themselves.

## A changed blood-protein profile

The response extended beyond the hormone assays. In a [2009 analysis of blood from eleven healthy young men](https://pubmed.ncbi.nlm.nih.gov/19386527/), several serum proteins changed after CJC-1295. Serum is the liquid part of blood left after clotting. Some protein signals correlated with IGF-1, offering possible markers of the hormonal response.

I appreciate the serum-protein study’s broader question. A longer hormonal signal leaves other measurable traces. The correlation does not establish that IGF-1 caused those protein changes, and the analysis did not demonstrate a health improvement. It adds a biological observation rather than a verdict about how someone feels.

## Identity required a laboratory

A [2010 report identified CJC-1295 in an unknown seized preparation](https://doi.org/10.1002/dta.233) using liquid chromatography and tandem mass spectrometry. Those techniques separate material and examine its molecular signature. This was analytical work in an anti-doping context, with no patients receiving ordinary treatment.

That paper is a useful interruption to any discussion that treats a compound name as sufficient identification. The authors had to establish what the material contained. A published result from an identified study compound cannot settle the contents of some other preparation.

![Mass spectrometer sample inlet and chromatography tubing on a laboratory bench](images/cjc-mass-spectrometer.webp)

*Illustrative laboratory still life, rather than the instrument or seized material from the identification paper.*

## CJC-1295 community accounts

Community accounts of CJC-1295 describe deeper sleep, easier recovery, puffiness, hand tingling and local irritation. These are anecdotal reports, not clinical evidence that CJC-1295 caused the changes. Mixed use of other substances, unclear compound identity and the DAC/no-DAC confusion make attribution especially difficult. The sleep accounts leave me curious, without a reliable estimate of how often an effect occurs.

CJC-1295 has no approved medical indication. Its small human studies establish [a sustained hormone response](https://pubmed.ncbi.nlm.nih.gov/16352683/), while leaving long-term safety inadequately characterized. Fluid retention, blood-sugar effects, immune reactions and the consequences of prolonged IGF-1 elevation remain concerns; the continuing pulses in [the secretion study](https://pubmed.ncbi.nlm.nih.gov/17018654/) cannot resolve them. CJC-1295 is prohibited in sport at all times.

I relish this experiment’s specificity: an altered molecule, a lasting response and a rhythm that survives. The [comparison with ipamorelin and tesamorelin](/compare) follows what happened when investigators asked for an outcome beyond that curve.

---

An independent reading of the growth-hormone signal as it ascends from receptor to evidence—an editorial digest, never a storefront or medical instruction.